# Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct04100434` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04100434](<https://clinicaltrials.gov/study/NCT04100434>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04100434

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

## Technical summary

Registry record NCT04100434. Randomized; double masking; primary purpose treatment. Start 2021-01-01 (anticipated); primary completion 2022-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT04100434, source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)
- Planned start: 2021-01-01 (anticipated) (ClinicalTrials.gov record NCT04100434, source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)
- Primary completion: 2022-06-01 (anticipated) (ClinicalTrials.gov record NCT04100434, source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)
- Completion: 2023-06-01 (anticipated) (ClinicalTrials.gov record NCT04100434, source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04100434, source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04100434-2020-11-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome
- Acronym: EMSIACS
- Condition: Acute Coronary Syndrome
- Condition: Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- Intervention (Drug): Evolocumab
- Lead sponsor: Tianjin Chest Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Tianjin Chest Hospital (`cardio:org-tianjin-chest-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes - exploratory analysis of the EMSIACS trial (`cardio:pubmed-41309899`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9c5dbf1caca42fb0d464e025bbea1475ce11a32f235ab0481a203b1aac5321ae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
